Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (05/20/2016)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Mature B-cell Non-Hodgkin Lymphoma (NHL)

Added text to state that BCL2 staining by immunohistochemistry is variable; the absence of a translocation involving BCL2 does not preclude the diagnosis of Burkitt lymphoma/leukemia and has no clinical implications (cited Masqué-Soler et al. as reference 9).

Anaplastic Large Cell Lymphoma

Added Strullu et al. as reference 31.

Added text to state that although complete responses are common, the necessary duration of therapy remains unclear (cited Gambacorti-Passerini et al. as reference 36 and level of evidence 3iiiDiii).

Rare NHL Occurring in Children

Added O'Suoji et al. as reference 2.

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section

Rare NHL Occurring in Children

Next section >

About This PDQ Summary

Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)—Health Professional Version - National Cancer Institute